Project Grant K25CA304623
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $164K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94305, USA
Similar Awards
- The National Cancer Institute awarded The Leland Stanford Junior University $644,703 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing) to develop a human bone marrow organoid culture method that sustains both normal and leukemic hematopoiesis. The project addresses a historic inability to culture hematopoietic stem cells, progenitors, and leukemic blasts beyond days to weeks by recapitulating the structurally and cellularly complex...
- The National Cancer Institute awarded Oregon Health & Science University $1,042,004 on March 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a microphysiological bone metastasis-on-a-chip platform that models prostate cancer metastasis into vascularized and innervated bone tissue. The research platform incorporates a mineralized, osteocyte-embedded bone matrix supporting active osteoclast and osteoblast remodeling, perfusable pericyte-supported vasculature to...
- The National Cancer Institute awarded The Leland Stanford Junior University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into the regulation of early breast cancer invasion by cancer-associated fibroblasts. The award funds research examining how cancer-associated fibroblasts (CAFs) and extracellular matrix remodeling drive the transition from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC). The recipient will conduct...
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The Leland Stanford Junior University $606,756 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development and validation of foundation model-augmented artificial intelligence tools to enable accurate and efficient image guidance in upright proton therapy for lung cancer treatment. The research will create a vision-language framework for...
- The National Cancer Institute awarded a $1.21 million cooperative agreement to The Leland Stanford Junior University on August 7, 2026, to support research on tumor-immune coevolution during metastatic progression under the Cancer Biology Research program (CFDA 93.396). The research investigates how tumors and lymphocytes undergo reciprocal adaptive evolution throughout metastasis, with focus on mechanisms by which early-stage metastatic tumors exploit immune education within lymph nodes to...
- The National Cancer Institute awarded The Leland Stanford Junior University $166,968 on August 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop single-molecule multi-omics sequencing methods for spatially resolved epigenetic profiling of extrachromosomal DNA (ecDNA) molecules and to investigate the relationship between ecDNA spatial organization, epigenetic landscape, and transcriptional regulation. The work addresses a technical gap in understanding ecDNA's...
- The National Cancer Institute awarded The Leland Stanford Junior University $550,897 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of tolerogenic macrophages in tumor metastasis, with particular focus on hepatic metastatic spread. The research examines how tumors educate local macrophages expressing the erythropoietin receptor (EPOR) to adopt an immunoregulatory phenotype through EPO signaling, creating a non-inflamed tumor microenvironment...
- The National Cancer Institute awarded The Leland Stanford Junior University $100,228 on February 13, 2027, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training and research in cancer immunotherapy. Performance extends through September 21, 2029, at Stanford's Palo Alto, California location. The award funds research on co-engineered CAR T cells and CAR macrophages for glioblastoma treatment. The project applies a synthetic cytokine receptor (SCR) platform to...
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...